During the reproductive period, mothers and offspring exchange hematopoietic cells and develop a form of immunological tolerance bidirectionally. To examine whether previous experience of such communication has any remote effect when maternal hematopoietic cells are later transplanted to the children, we retrospectively compared the outcomes of blood and marrow stem cell transplantation from maternal donors (n = 46) to those from paternal donors (n = 50) by using the database of the Japanese nationwide surveys for adult hematopoietic cell transplants between 1990 and 1998. At 5 years, recipients of maternal hematopoietic cells had a significantly higher overall survival than patients receiving paternal grafts (60% vs 32%, P = 0.006). Although no significant difference was observed in the occurrence of severe acute GVHD (grade уIII) and the relapse of malignant diseases between two groups, the probability of non-relapse treatment-related mortality was significantly lower after maternal donor transplants. Furthermore, multivariate analysis revealed that parental donor type was the only factor significantly associated with overall survival. In conclusion, our analysis indicates superior survival of maternally donated recipients in hematopoietic stem-cell transplantations from biological parents. This finding has important implications in the selection of alternative familial donors, and warrants further prospective analysis of parental donor transplantations. Bone Marrow Transplantation (2001) 28, 375-380.
Allogeneic hematopoietic stem cell transplantation after myeloablative or nonmyeloablative chemoradiotherapy is a potentially curative treatment for various hematologic and hereditary diseases. 1, 2 Since the availability of an HLAidentical sibling donor is often limited, most patients eligible for allogeneic stem cell transplants have to seek an alternative donor who is not fully histocompatible with themselves.
3-5 HLA-phenotypically matched or partiallymismatched parents represent an important stem-cell source for such patients, because both mother and father genetically share at least one HLA haplotype with their children.
Maternal and paternal donations differ in the transplant situation because only the mother-child pair has had the opportunity to establish bidirectional immunological tolerance during pregnancy and maybe thereafter. For example, maternal peripheral blood lymphocytes were shown to be immunologically unresponsive to those of the infant for several months following delivery. 6 On the other hand, about half of the patients receiving multiple transfusions as adults did not form antibodies against the non-inherited maternal HLA antigens, 7 indicating the persistence of acquired B cell unresponsiveness to maternal antigens into adult life. More surprisingly, semi-allogeneic fetal hematopoietic cells were detectable from parous women not only during gestation but also many years after childbirth, [8] [9] [10] [11] suggesting a long-lasting form of the maternal tolerance to fetal HLA antigens of paternal origin.
To date, the role of such previous experience of maternal-fetal tolerance in allogeneic hematopoietic stem cell transplantation is unknown. However, several reports on solid allograft transplants have suggested the persistence of a favorable 'maternal-fetal effect' even after the cessation of pregnancy. A recent analysis of renal transplants between HLA-haploidentical siblings demonstrated a possible association of tolerance to non-inherited maternal HLA antigens with better survival of the renal allografts. 12 In addition, a study on pediatric renal transplants from biological parents revealed that time to first rejection was significantly longer in patients less than 1 year of age receiving maternal organs, although overall graft survival was not significantly different between maternal and paternal donations. 13 With these clinical observations in mind, it is crucial to examine the possible influence of a maternal effect on the outcome of adult hematopoietic stem cell transplants in which histo-incompatibility is a major factor for treatment failure. We therefore compared the survival of bone marrow and peripheral blood progenitor cell recipients given phenotypically HLA-matched or partially-mismatched maternal grafts with those given paternal grafts.
Patients and methods

Patients
At present, a total of 287 hematopoietic stem cell transplant centers (all in Japan) are affiliated with the Japan Society for Hematopoietic Cell Transplantation (JSHCT). 14 Participants must report detailed data on all consecutive hematopoietic transplants of any type. Since 1993, data have been annually collected by the Office of Nationwide Surveys (Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya) of the JSHCT and, as of December 1999, the dataset included 8096 transplants for adult patients (aged у15 years) performed between January 1990 and December 1998. Among this JSHCT dataset for adults, 90 patients with hematological malignant diseases and six patients with severe aplastic anemia were identified as having been transplanted from their biological parents with bone marrow or mobilized peripheral blood stem cells. Characteristics of these recipients included in the following analyses are shown in Table 1 .
Outcome
Outcome was measured in terms of overall survival (OS), acute GVHD, and transplant-related mortality for all patients. Furthermore, disease-free survival (DFS) and relapse rate were additionally evaluated in patients with malignant hematological diseases, including acute leukemia, chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), and non-Hodgkin's lymphoma (NHL). Patients were considered evaluable for acute GVHD at the time of engraftment. Acute GVHD was defined on the basis of standard criteria. 15 
Statistical analysis
All statistical analyses were performed by using STATA (STATA Corporation, College Station, TX, USA). The chisquare test was employed to examine the independence between two categorical variables, with the Mann-Whitney test used for variance of age. Actuarial overall survival was estimated by the Kaplan-Meier product-limit analysis, 16 and differences in survival were tested by the log-rank test. Univariate and multivariate analyses for survival outcomes were performed using proportional hazards models. 17 Logistic regression was employed for evaluation of relative risk for acute GVHD. Factors used for multivariate analyses were as follows: parental donor type, recipient sex, HLAmatching status, conditioning regimen, GVHD prophylaxis, type of stem cell source, and risk category at transplant. Patients with acute leukemia in first remission, CML in first chronic phase, NHL in first remission, and MDS in refractory anemia were considered to have standard-risk disease and all others were considered to have a high-risk disease at transplant excluding three patients whose remission status was not reported. A significance level of a P value less than 0.05 was used for all analyses. Table 1 shows the baseline characteristics of the recipients of parental blood and marrow transplants. Of the 96 patients, 50 received paternal hematopoietic stem cells and 46 received maternal cells. The two groups had similar characteristics in terms of demographic features, disease status at transplant, HLA compatibility and conditioning regimen, although some heterogeneity was observed in diagnoses, type of stem cell source, and GVHD prophylaxis (none was statistically significant). Among the 50 paternally donated patients, 46 had hematological malignant diseases and four had aplastic anemia. Of the 46 recipients of maternal grafts, 44 had malignant diseases and two had aplastic anemia. The proportion of patients having a highrisk malignant disease at transplant was similar in the paternally donated and maternally donated groups. Figure 1 shows the probability of overall survival in parental blood and marrow recipients according to parental donor type. There was a significant difference in 5-year overall survival between maternally donated and paternally donated recipients (60% vs 32%, P = 0.006 by the log-rank test), indicating higher survival of the recipients of maternal hematopoietic cells. The superior survival in recipients of maternal donations persisted after adjustment for recipient demographic characteristics, HLA compatibility, risk category at transplant, conditioning, GVHD prophylaxis, and type of stem cell source according to a multivariate proportional hazards model (adjusted hazard ratio for maternal vs paternal donation 0.50, (95% CI 0.27-0.93); P = 0.03). Multivariate analysis also revealed that parental donor type was the only variable significantly associated with overall survival. Probability of overall survival in recipients of paternal and maternal hematopoietic cells in HLA-matched and HLA-mismatched settings are shown separately in Figure 2 . Better survival of maternally donated recipients was more striking when transplants were performed between HLA-mismatched pairs, although this was not statistically significant (64% for transplants from HLA-mismatched mothers; 25% for transplants from HLAmismatched fathers, P = 0.08).
Results
Patient characteristics
Overall survival
Acute GVHD
Sixty-six of 93 (71%) evaluable patients developed acute GVHD. Grades II to IV GVHD was observed in 15 paternally donated patients (grade II in eight and grade III in Bone Marrow Transplantation seven) and 17 maternally donated patients (grade II in nine, grade III in four, and grade IV in four). There was no statistically significant difference between paternally donated and maternally donated groups in overall incidence of either grades II to IV (P = 0.61) or grades III to IV acute GVHD (P = 0.74). On univariate analysis, transplant from an HLA-mismatched donor (odds ratio for HLAmismatched vs HLA-matched transplant 4.72 (95% CI 1.44-15.4); P = 0.01) and the use of PBSC (odds ratio for PBSC vs bone-marrow 6.72 (95% CI 1.46-30.9); P = 0.01) were found to be significantly associated with an increased risk of grades III to IV acute GVHD. When adjusted by multivariate analysis, HLA-mismatching was the only factor significantly associated with the occurrence of grades III to IV GVHD (odds ratio for HLA-mismatched graft vs HLA-matched graft 3.84 (95% CI 1.03-14.4); P = 0.04). Although parental donor type was not significantly associated with the incidence of acute GVHD on univariate analysis, maternally donated patients were found to be at higher risk of developing grades II to IV GVHD (odds ratio for maternal vs paternal donation 3.28 (95% CI; 1.08-9.85); P = 0.036) when adjusted by multivariate analysis. Among patients who had developed grades II to IV acute GVHD, 12 of 15 paternally donated patients and eight of 17 maternally donated recipients had eventually died, and maternal donation was significantly associated with better overall survival (hazard ratio 0.38 (95% CI 0.15-0.95); P = 0.039) in this group of patients.
Relapse and treatment-related mortality
Because the outcomes in the recipients of paternal and maternal hematopoietic stem cells were appreciably different without significant variance in the occurrence of severe acute GVHD, we examined whether parental donor type would affect the incidence of relapse or treatment-related mortality not associated with relapse among 90 patients with hematological malignant diseases. On univariate analysis, treatment-related non-relapse mortality was considerably lower in transplants from mothers (hazard ratio for maternal vs paternal donation 0.33 (95% CI 0.15-0.75); P = 0.008), although the probability of relapse was not significantly different between the two groups (hazard ratio for maternal vs paternal donation 0.73 (95% CI 0.27-1.96); P = 0.54). The other adverse prognostic factor for treatment-related mortality on univariate analysis was HLA incompatibility, while no factors were found to be associated with relapse. The lower incidence of non-relapse death among maternally donated recipients was also confirmed on multivariate analysis (Table 2) , which demonstrated that donations from fathers (P = 0.026) or the use of HLA-mismatched grafts (P = 0.033) were associated with significantly higher risk for treatmentrelated mortality. Multivariate analysis also suggested better disease-free survival of maternally donated patients (P = 0.053) and a lower relapse risk in recipients of HLAmismatched grafts (P = 0.051) among patients with malignant hematological diseases. Table 2 Multivariate analysis of the factors influencing relapse, treatment-related non-relapse mortality, and disease-free survival after parental donor blood and marrow transplantation for patients with malignant hematological disease 
Discussion
In this retrospective analysis, we found a superior longterm survival of patients who had received maternally rather than paternally derived bone marrow or peripheral blood hematopoietic stem cells. Although patients given maternal grafts and paternal grafts had similar clinical backgrounds, including the proportion of high-risk malignant diseases at transplant, maternal donation was significantly associated with higher overall survival and lower treatment-related mortality on both univariate and multivariate analyses. Of particular interest, although HLAincompatibility was another significant prognostic factor associated with treatment-related non-relapse death in our series, better survival of maternally donated recipients was more noticeable when transplants were performed between HLA-mismatched pairs. To our knowledge, this is the first report that has identified an impact of parental donor type on overall survival after allogeneic hematopoietic stem-cell transplantation in adults.
Based on the hypothesis that the immunological tolerance between mother and fetus gives rise to a form of actively acquired bilateral tolerance which is maintained even after the pregnancy, some investigators have attempted to demonstrate the potential benefit of using maternal material in the setting of transplantation of solid organs or hematopoietic cells. 13, 18 Although there have been a number of conflicting debates on this 'maternal-fetal effect', originally reported as specific B cell unresponsiveness to non-inherited maternal HLA antigens in heavily transfused adult patients, 7 recent clinical observations have begun to substantiate the post-partum persistence of such bidirectional tolerance which appears to have important implications in human transplantation medicine. Umbilical cord blood mononuclear cells have been demonstrated to produce different phenotypes of cytotoxic lymphocytes when exposed to maternal or paternal cells, 19 and reported to show weaker alloreactive responses to maternal blood cells than to paternal cells. 20 Peripheral blood lymphocytes from mother and infant still exhibited markedly depressed responses to one another even at 6 months following delivery. 6 Moreover, it was reported that fully HLAhaploincompatible non-T cell-depleted hematopoietic stemcell transplants, which were usually accompanied by lifethreatening severe GVHD, were feasible when maternal bone marrow was transplanted to the children with peritransplant administration of anti-thymocyte globulin. 18 Consistent with these reports suggesting a long-standing immunological advantage of the mother-child union, we demonstrated in this study the excellent survival of recipients of maternal blood and marrow, in comparison with the patients given paternal blood stem cells. However, our analysis also indicated that this effect was not simply due to hyporesponsiveness between mother and child. First, the probability of developing acute GVHD was not lower in the maternally donated patients when compared to the recipients of paternal blood cells. Second, relapse risk of malignant hematological diseases was not significantly different between the two groups, suggesting that an allogeneic 'graft-versus-leukemia/lymphoma' effect was not adversely affected by maternal tolerance to fetal histocompatibility antigens. Why then, was the transplantation of maternal hematopoietic cells associated with better survival in the recipients?
One possible mechanism is a 'protective' effect of the maternal hematopoietic cells in promoting resolution of acute GVHD or concomitant immunodysregulation. Indeed, although maternal donation was found to be more commonly associated with grades II to IV acute GVHD than paternal donation on multivariate analysis, the incidence of severe grade III or IV GVHD was not significantly different between the two groups, and among the recipients who had developed grades II to IV acute GVHD, patients receiving maternal grafts had a higher overall survival than did those receiving paternal grafts. A similar, paradoxical finding was also observed on analysis of renal allograft transplants from HLA-haploidentical siblings expressing paternal or maternal HLA antigens which the recipient did not inherit. 12 In that study, patients who were given renal grafts expressing non-inherited maternal HLA antigens experienced a higher incidence of acute rejection, which could be considered as an immunological 'priming' effect evoked by the previously experienced maternal antigens. To clarify the mechanism by which transplantation of maternal blood and marrow is linked to a more favorable outcome with lower transplant-related mortality, we need to reconsider the significance of long-term maternal-fetal hematopoietic cell microchimerism. By using highly sensitive PCR for Ychromosome-specific or HLA-specific DNA, several groups have demonstrated the long-term presence of fetal CD34 + CD38 + blood progenitor cells and multi-lineage fetal hematopoietic cell microchimerism in post-partum maternal blood. [8] [9] [10] Because it is well-known that donor hematopoietic cell microchimerism is associated with excellent allograft survival in human solid organ transplants and experimental animal models, 21, 22 it is reasonable to hypothesize that the presence of fetal cell microchimerism in the Bone Marrow Transplantation maternal blood might be an indicator of persistent tolerance to the fetal antigens of paternal origin.
In conclusion, our results demonstrate the superior survival of blood and marrow recipients of maternal grafts over those receiving paternal grafts. Further analysis is warranted to clarify the mechanisms and role of a long-term 'feto-maternal' effect in allogeneic hematopoietic cell transplantation between family members.
